Actualités TC BioPharm Holdings PLC - TCBP | Actions NASDAQ

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum

TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO...

TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial

TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial PR Newswire EDINBURGH...

TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial

TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial PR...

TCBP to Implement ADS Ratio Change

TCBP to Implement ADS Ratio Change PR Newswire EDINBURGH, Scotland, Feb. 5, 2025 EDINBURGH, Scotland, Feb. 5...

TCBP Announces H5N1 Proof of Concept Studies Intention

TCBP Announces H5N1 Proof of Concept Studies Intention PR Newswire EDINBURGH, Scotland, Jan. 15, 2025...

TCBP to Present at Sequire Investor Summit 2025

TCBP to Present at Sequire Investor Summit 2025 PR Newswire EDINBURGH, Scotland, Jan. 13, 2025 EDINBURGH...

/C O R R E C T I O N -- TC BioPharm/

/C O R R E C T I O N -- TC BioPharm/ PR Newswire EDINBURGH, Scotland, Dec. 30, 2024 In the news release, TCBP...

TCBP Trading Continues Unabated on Nasdaq Stock Exchange

TCBP Trading Continues Unabated on Nasdaq Stock Exchange PR Newswire EDINBURGH, Scotland, Jan. 6, 2025...

TCBP Provides Update on Acquisition Strategy and Current Targets

TCBP Provides Update on Acquisition Strategy and Current Targets PR Newswire EDINBURGH, Scotland, Dec. 31...

TCBP Issues 25% Stock Dividend

TCBP Issues 25% Stock Dividend PR Newswire EDINBURGH, Scotland, Dec. 30, 2024 EDINBURGH, Scotland, Dec. 30...

TCBP Advances ACHIEVE Phase 2b Clinical Trial with Final Dosing of 3 Patients

TCBP Advances ACHIEVE Phase 2b Clinical Trial with Final Dosing of 3 Patients PR Newswire EDINBURGH, Scotland...

TCBP Announces General Meeting of Shareholders to Approve One-Time Shareholder Dividend

TCBP Announces General Meeting of Shareholders to Approve One-Time Shareholder Dividend PR Newswire EDINBURGH...

TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy

TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of...

TCBP Provides Quarterly Update on the ACHIEVE (UK) Clinical Trial

TCBP Provides Quarterly Update on the ACHIEVE (UK) Clinical Trial PR Newswire EDINBURGH, Scotland, Dec. 4...

TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant

TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant PR Newswire EDINBURGH, Scotland, Nov. 12, 2024...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

TC BioPharm Holdings PLC (TCBP)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

TCBP Actualités

TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum

TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial

TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial

TCBP to Implement ADS Ratio Change

TCBP Announces H5N1 Proof of Concept Studies Intention

TCBP to Present at Sequire Investor Summit 2025

/C O R R E C T I O N -- TC BioPharm/

TCBP Trading Continues Unabated on Nasdaq Stock Exchange

TCBP Provides Update on Acquisition Strategy and Current Targets

TCBP Issues 25% Stock Dividend

TCBP Advances ACHIEVE Phase 2b Clinical Trial with Final Dosing of 3 Patients

TCBP Announces General Meeting of Shareholders to Approve One-Time Shareholder Dividend

TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy

TCBP Provides Quarterly Update on the ACHIEVE (UK) Clinical Trial

TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

TC BioPharm Holdings PLC (TCBP) Actualités

TC BioPharm Holdings PLC (TCBP)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

TCBP Actualités

TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum

TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial

TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial

TCBP to Implement ADS Ratio Change

TCBP Announces H5N1 Proof of Concept Studies Intention

TCBP to Present at Sequire Investor Summit 2025

/C O R R E C T I O N -- TC BioPharm/

TCBP Trading Continues Unabated on Nasdaq Stock Exchange

TCBP Provides Update on Acquisition Strategy and Current Targets

TCBP Issues 25% Stock Dividend

TCBP Advances ACHIEVE Phase 2b Clinical Trial with Final Dosing of 3 Patients

TCBP Announces General Meeting of Shareholders to Approve One-Time Shareholder Dividend

TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy

TCBP Provides Quarterly Update on the ACHIEVE (UK) Clinical Trial

TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités